Urologix' BPH (benign prostatic hyperplasia) therapy effective in half the time:
This article was originally published in Clinica
Executive Summary
Two-year trial data have revealed that Urologix' shortened, cooled thermotherapy system, Targis, is as effective in treating non cancerous prostate growth, in under 30 minutes, compared with the alternative 60-minute treatment. In a randomised trial of 94 men with benign prostatic hyperplasia (BPH), there was no significant difference between the conventional 60-minute and 28.5-minute Targis treatment, reported researchers from the University of Texas Southwestern, Dallas, Texas. The factors assessed included symptom score, peak urinary flow or quality of life.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.